Immunome Inc
Ownership
Ownership Structure
Who owns Immunome Inc (IMNM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 92.1% of the shares are freely tradable; institutional investors hold 108.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 17.35 | 19,676,883 | +20.2 | 06/30/2026 |
| FMR Inc | 14.98 | 16,987,553 | +0.1 | 06/30/2026 |
| BlackRock Inc | 7.77 | 8,805,492 | +7.8 | 06/30/2026 |
| State Street Corp | 4.85 | 5,494,625 | +1.8 | 06/30/2026 |
| Wellington Management Company LLP | 4.59 | 5,210,216 | +10.1 | 06/30/2026 |
| Redmile Group, LLC | 4.33 | 4,911,590 | -11.6 | 06/30/2026 |
| PRIMECAP Management Company | 4.04 | 4,581,431 | -4.3 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.01 | 4,551,289 | +2.7 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 6.51 | 7,377,639 | +0.2 | 09/30/2026 |
| Fidelity Growth Company Fund | 4.32 | 4,903,773 | +0.3 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Siegall Clay B | President and CEO | 870,704 | 17,675,291 $ | Jul 23, 2026 | direct |
| Rosett Max | Chief Financial Officer | 101,287 | 2,056,126 $ | Jul 23, 2026 | direct |
| Barchas Isaac | Director | 92,211 | 1,871,883 $ | Aug 11, 2026 | both |
| Tsai Philip | Chief Technical Officer | 81,550 | 1,655,465 $ | Jul 23, 2026 | direct |
| Lechleider Robert | Chief Medical Officer | 69,805 | 1,417,042 $ | Jul 23, 2026 | direct |
| Higgins Jack | Chief Scientific Officer | 56,250 | 1,141,875 $ | Sep 11, 2026 | direct |
| Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | 43,805 | 889,242 $ | Jul 23, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | Other | 8,800 | 0.00 | – |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | Sell | 13,200 | 25.32 | 334,224 |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | Other | 18,000 | 1.35 | 24,300 |
| Aug 12, 2026 | Barchas Isaac | Director | Sell | 11,048 | 27.25 | 301,058 |
| Aug 11, 2026 | Barchas Isaac | Director | Sell | 62,291 | 26.23 | 1,633,893 |
| Aug 10, 2026 | Barchas Isaac | Director | Sell | 10,125 | 26.07 | 263,959 |
| Aug 7, 2026 | Barchas Isaac | Director | Sell | 15,248 | 26.06 | 397,363 |
| Aug 6, 2026 | Barchas Isaac | Director | Sell | 20,840 | 26.06 | 543,090 |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 90,616 | 25.09 | 2,273,555 |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 40,250 | 10.60 | 426,650 |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 50,366 | 12.92 | 650,729 |
| Jul 23, 2026 | Tsai Philip | Chief Technical Officer | Other | 38,250 | 0.00 | – |
| Jul 23, 2026 | Lechleider Robert | Chief Medical Officer | Other | 54,000 | 0.00 | – |
| Jul 23, 2026 | Rosett Max | Chief Financial Officer | Other | 47,250 | 0.00 | – |
| Jul 23, 2026 | Higgins Jack | Chief Scientific Officer | Other | 38,250 | 0.00 | – |
| Jul 23, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 31,250 | 0.00 | – |
| Jul 23, 2026 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Other | 38,250 | 0.00 | – |
| Jul 23, 2026 | Siegall Clay B | President and CEO | Other | 180,000 | 0.00 | – |
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 1,092 | 25.00 | 27,300 |
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 1,092 | 12.92 | 14,109 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.